Pfizer Inc. and UCSF will expand a 2-1/2-year-old drug-research deal to include small molecules, making it possibly the only academic-industry research collaboration encompassing oral small-molecule drugs as well as large-molecule biologics.
The arrangement, which could fund lab projects as soon as the third quarter, comes at a time when Big Pharma players such as Pfizer, the world's largest drug maker, are seeking to restock their drug pipelines. Read the full story.